Pascale Witz's most recent trade in Regulus Therapeutics Inc was a trade of 62,500 Common Stock done . Disclosure was reported to the exchange on April 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Regulus Therapeutics Inc | Pascale Witz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2025 | 62,500 | 67,233 (0%) | 0% | 0 | Common Stock | |
| Revvity | Pascale Witz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2025 | 1,338 | 13,705 (0%) | 0% | 0 | Common Stock | |
| Revvity | Pascale Witz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2025 | 1,074 | 12,367 (0%) | 0% | 0 | Common Stock | |
| Regulus Therapeutics Inc | Pascale Witz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2024 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Pascale Witz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Revvity | Pascale Witz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 1,218 | 11,293 (0%) | 0% | 0 | Common Stock | |
| Revvity | Pascale Witz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2024 | 977 | 10,075 (0%) | 0% | 0 | Common Stock | |
| Regulus Therapeutics Inc | Pascale Witz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Pascale Witz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Revvity | Pascale Witz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 955 | 9,098 (0%) | 0% | 0 | Common Stock | |
| Revvity | Pascale Witz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 783 | 8,143 (0%) | 0% | 0 | Common Stock | |
| Horizon Therapeutics Plc | Pascale Witz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2023 | 3,913 | 0 | - | - | Restricted Stock Units | |
| Horizon Therapeutics Plc | Pascale Witz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2023 | 3,913 | 18,202 (0%) | 0% | - | Ordinary Shares | |
| Horizon Therapeutics Plc | Pascale Witz | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 111.16 per share. | 28 Apr 2023 | 1,879 | 16,323 (0%) | 0% | 111.2 | 208,870 | Ordinary Shares |
| Regulus Therapeutics Inc | Pascale Witz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Revvity | Pascale Witz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2022 | 744 | 7,360 (0%) | 0% | 0 | Common Stock | |
| Revvity | Pascale Witz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2022 | 610 | 6,616 (0%) | 0% | 0 | Common Stock | |
| Horizon Therapeutics Plc | Pascale Witz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2022 | 4,223 | 45,575 (0%) | 0% | - | Ordinary Shares | |
| Horizon Therapeutics Plc | Pascale Witz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2022 | 4,223 | 0 | - | - | Restricted Stock Units | |
| Horizon Therapeutics Plc | Pascale Witz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2022 | 3,913 | 3,913 | - | - | Restricted Stock Units | |
| Horizon Therapeutics Plc | Pascale Witz | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 98.56 per share. | 28 Apr 2022 | 1,658 | 43,917 (0%) | 0% | 98.6 | 163,412 | Ordinary Shares |
| Revvity | Pascale Witz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2021 | 709 | 6,006 (0%) | 0% | 0 | Common Stock | |
| Revvity | Pascale Witz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2021 | 604 | 5,297 (0%) | 0% | 0 | Common Stock | |
| Horizon Therapeutics Plc | Pascale Witz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2021 | 11,098 | 0 | - | - | Restricted Stock Units | |
| Horizon Therapeutics Plc | Pascale Witz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2021 | 11,098 | 45,709 (0%) | 0% | - | Ordinary Shares | |
| Horizon Therapeutics Plc | Pascale Witz | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 94.62 per share. | 29 Apr 2021 | 4,357 | 41,352 (0%) | 0% | 94.6 | 412,259 | Ordinary Shares |
| Horizon Therapeutics Plc | Pascale Witz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Apr 2021 | 4,223 | 4,223 | - | - | Restricted Stock Units | |
| Horizon Therapeutics Plc | Pascale Witz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2020 | 8,204 | 0 | - | - | Restricted Stock Units | |
| Horizon Therapeutics Plc | Pascale Witz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2020 | 8,204 | 37,832 (0%) | 0% | - | Ordinary Shares | |
| Horizon Therapeutics Plc | Pascale Witz | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 61.19 per share. | 02 Aug 2020 | 3,221 | 34,611 (0%) | 0% | 61.2 | 197,093 | Ordinary Shares |